http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
( Hideyuki Tamai ),( Yoshiyuki Ida ),( Akira Kawashima ),( Naoki Shingaki ),( Ryo Shimizu ),( Kosaku Moribata ),( Tetsushi Nasu ),( Takao Maekita ),( Mikitaka Iguchi ),( Jun Kato ),( Taisei Nakao ),( 대한간학회 2017 Gut and Liver Vol.11 No.4
Background/Aims: The present study aimed to evaluate the safety and efficacy of simeprevir-based triple therapy with reduced doses of pegylated interferon (PEG-IFN) and ribavirin for interferon (IFN) ineligible patients, such as elderly and/or cirrhotic patients, and to elucidate the factors contributing to a sustained virologic response (SVR). Methods: One hundred IFN ineligible patients infected with genotype 1b hepatitis C virus (HCV) were treated. Simeprevir (100 mg) was given orally together with reduced doses of PEG-IFN-α 2a (90 μg), and ribavirin (200 mg less than the recommended dose). Results: The patients` median age was 70 years, and 70 patients were cirrhotic. Three patients (3%) discontinued treatment due to adverse events. The SVR rate was 64%. Factors that significantly contributed to the SVR included the γ-glutamyl transferase and α-fetoprotein levels, interleukin- 28B (IL28B) polymorphism status, and the level and reduction of HCV RNA at weeks 2 and 4. The multivariate analysis showed that the IL28B polymorphism status was the only independent factor that predicted the SVR, with a positive predictive value of 77%. Conclusions: Simeprevir-based triple therapy with reduced doses of PEG-IFN and ribavirin was safe and effective for IFN ineligible patients infected with genotype 1b HCV. IL28B polymorphism status was a useful predictor of the SVR. (Gut Liver 2017;11:551-558)
만성C형간염 : 만성 C형 간염의 치료: 주사제를 포함한 요법
김경아 대한간학회 2014 간학회 싱글토픽 심포지움 Vol.2014 No.1
With the development of direct acting antivirals (DAAs), the outcomes of hepatitis C treatment have been improved. Triple therapy including peginterferon, ribavirin and boceprevir or telaprevir is the current standard of care for genotype 1 infection in United States and Europe. Recently, sofosbuvir, a nucleotide analogue NS5B polymerase inhibitor and simeprevir, a NS3A protease inhibitor were approved by FDA. Overall SVR was 90% with combination therapy of sofosbuvir, peginterferon and ribavirin for 24 weeks. SVR was 80% for genotype 1 infection with the combination therapy of simepervir, peginterferon and ribavirin. Several DAAs with different viral targets are under clinical trials in various combination including interferon-free regimens.